The relationship between systemic inflammation and increased left ventricular mass is partly mediated by noncalcified coronary artery disease burden in psoriasis

Wunan Zhou\textsuperscript{a}, Meron Teklu\textsuperscript{a}, Vy Bui\textsuperscript{a}, Grigory A. Manyak\textsuperscript{a}, Promita Kapoor\textsuperscript{a}, Amit K. Dey\textsuperscript{a}, Alexander V. Sorokin\textsuperscript{a}, Nidhi Patel\textsuperscript{a}, Heather L. Teague\textsuperscript{a}, Martin P. Playford\textsuperscript{a}, Julie Erb-Alvarez\textsuperscript{a}, Justin A. Rodante\textsuperscript{a}, Andrew Keel\textsuperscript{b}, Sujata M. Shanbhag\textsuperscript{a}, Li-Yueh Hsu\textsuperscript{b}, David A. Bluemke\textsuperscript{c}, Marcus Y. Chen\textsuperscript{c}, Marcus Carlsson\textsuperscript{a}, Nehal N. Mehta\textsuperscript{a,\textsuperscript{*}}

\textsuperscript{a} National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States
\textsuperscript{b} Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, United States
\textsuperscript{c} Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States

\textbf{A R T I C L E   I N F O}

\textbf{Keywords:}
Inflammation
Left ventricular mass
Noncalcified coronary burden
Cardiac computed tomography angiography

\textbf{A B S T R A C T}

\textbf{Objective:} Increased left ventricular (LV) mass is an important precursor to heart failure. Inflammation plays an important role in increasing LV mass. However, the contribution of subclinical coronary artery disease (CAD) to the inflammation-LV mass relationship is unknown. In subjects with psoriasis, a chronic inflammatory skin disease, we evaluated if systemic inflammation assessed by plasma glycoprotein A (GlycA) associated with LV mass measured on coronary CT angiography (CCTA). Additionally, we analyzed whether this relationship was mediated by early CAD assessed as noncalcified coronary burden (NCB).

\textbf{Methods:} We performed an observational longitudinal study of 213 subjects with psoriasis free of known cardiovascular disease, 189 of whom were followed over one year. All had GlycA measurements by nuclear magnetic resonance spectroscopy and LV mass and NCB quantified by CCTA.

\textbf{Results:} The cohort had a mean age of 50.3 (±12.9) years and 59% were male. There was moderate psoriasis severity and low cardiovascular risk. LV mass increased by GlycA tertiles [1st tertile:24.6 g/m\textsuperscript{2}(3.8), 2nd tertile:25.5 g/m\textsuperscript{2}(3.8), 3rd tertile:27.7 g/m\textsuperscript{2}(5.5), p<0.001]. Both GlycA (β=0.24, p=0.001) and NCB (β=0.50, p<0.001) associated with LV mass in models adjusted for age, sex, hypertension, hypertension therapy, lipid therapy, biologic therapy for psoriasis, waist:hip ratio, psoriasis disease duration and severity. In multivariable-adjusted mediation analyses, NCB accounted for 32% of the GlycA-LV mass relationship. Finally, over one year, change in NCB independently associated with change in LV mass (β=0.25, p=0.002).

\textbf{Conclusions:} Both systemic inflammation and coronary artery NCB were associated with LV mass beyond cardiovascular risk factors in psoriasis. Furthermore, a substantial proportion of the inflammatory-LV mass relationship was mediated by NCB. These findings underscore the possible contribution of early coronary artery disease to the relationship between systemic inflammation and LV mass.

\textbf{Abbreviations:} LV, left ventricular; CCTA, cardiac computed tomography angiography; NCB, noncalcified coronary burden; GlycA, glycoprotein A; hs-CRP, high sensitivity-C reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

\textsuperscript{*} Corresponding author at: Lasker Senior Investigator, Chief, Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

\textit{E-mail address:} nehal.mehta@nih.gov (N.N. Mehta).

https://doi.org/10.1016/j.ajpc.2021.100211
Received 25 March 2021; Received in revised form 24 May 2021; Accepted 26 May 2021
2666-6677/Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
1. Introduction

Chronic systemic inflammation plays an important role in the pathogenesis of increased left ventricular (LV) mass and heart failure.[1,2] Psoriasis is an inflammatory skin disease associated with systemic inflammation, premature atherosclerosis, and heart failure.[3,4] Thus, psoriasis serves as a useful human disease model to investigate the relationship between chronic inflammation and LV mass, and determine whether early coronary artery disease (CAD) in the form of noncalcified coronary burden (NCB) may partly account for the inflammation-LV mass relationship.

Early human studies detected elevated plasma inflammatory cytokines in heart failure[5] while preclinical studies characterized the role of the innate immune system in the development of heart failure.[6] GlycA, a nuclear magnetic resonance (NMR) spectroscopy-derived composite biomarker of chronic inflammation, has been shown to associate with subclinical CAD assessed as NCB by coronary CT angiography (CCTA),[7] and also recently shown to promote adverse LV remodeling and heart failure.[2] Furthermore, GlycA has been shown to predict adverse cardiovascular events[8] independent of high sensitivity C-reactive protein (hs-CRP).[9] In states of chronic inflammation including psoriasis, GlycA captures cardiometabolic risk at least as much as hs-CRP,[7] making it an attractive blood systemic inflammatory biomarker for cardiovascular risk assessment.

Inflammation drives myocardial abnormalities via endothelial inflammation, which induces myocardial hypertrophy, cardiomyocyte stiffening and increased interstitial fibrosis.[10] However, few studies have directly investigated whether the association between inflammation and early myocardial abnormalities is mediated by the presence of subclinical CAD. Thus, in an ongoing cohort study to assess the association between varying degrees of psoriasis severity over time and the development of cardiometabolic diseases in subjects free of clinical cardiovascular disease (CVD), we hypothesized that circulating GlycA would associate with LV mass assessed using a fully automated, artificial intelligence (AI) software for LV segmentation on cardiac computed tomography angiography (CCTA). Furthermore, we hypothesized that NCB would partly mediate the inflammation-LV mass relationship beyond cardiovascular risk factors and that a change in NCB over one-year follow-up would associate with a favorable change in LV mass.

2. Methods

2.1. Study design and participants

The study consisted of 336 consecutive participants recruited from January 1, 2013 to August 11, 2020 as part of the Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI), an ongoing cohort study of participants with psoriasis. The general objective of this cohort study is to assess the association between varying degrees of psoriasis severity over time and the development of cardiometabolic diseases. A priori, as part of the CCTA analyses, our protocol stated that we would analyze the impact of inflammation on LV characteristics over time. At the time of analyses, 213 had CCTA results for LV mass, NCB, and GlycA measurements with 189 participants having one-year follow data available of these parameters (Fig. 1). PACI consists of asymptomatic, community-dwelling adults with psoriasis and without active cardiac disease at time of recruitment. Participants were excluded if they had an estimated glomerular filtration rate <30 mL/min/1.73m², any comorbid condition known to promote CVD or systemic inflammation, such as uncontrolled hypertension, internal malignancy within 5 years, human immunodeficiency virus, active infection within the past 72 h of base-
fusion to label various cardiovascular structures. It then performs several computer vision algorithms to refine different cardiac labels and obtain the final segmentation. The LV mass was calculated in grams from the LV myocardium size (in mm²) multiplied by a myocardial tissue density of 1.05 g/ml. Comparison between automated segmentation and manual segmentation by expert cardiologists based on 21 randomly selected studies showed excellent correlation with an average intraclass correlation coefficient (ICC) of 0.99 and r of 0.99. LV mass was normalized to height to an allometric power of 2.7 given prior studies which show this indexing method more accurately identifies left ventricular hypertrophy in overweight and obese individuals.[15]

2.5. Coronary artery characterization on cardiac computed tomography angiography

An expert cardiologist read the scans to determine presence or absence of coronary plaque via visual assessment. Readers blinded to subject demographics and scan time evaluated coronary artery characteristics of each main coronary artery >2 mm in diameter in core lab fashion. Semi-automated contouring with manual adjustment of the inner lumen and outer wall was performed using dedicated software (QAngio CT; Medis, The Netherlands).[4] Transverse reconstructed cross-sections of the artery were reviewed at 0.5 mm increments. The adaptive threshold which considers varying Hounsfield unit intensities throughout the entire vessel was used due to increased independence of lumen contrast intensity when compared to fixed threshold methods.[16] Segmental coronary artery volume (mm³) was divided by segment length (mm) and attenuated for luminal intensity to derive noncalcified coronary burden and dense calcified coronary burden. All noncalcified coronary burden, dense calcified coronary burden and total coronary burden values indicate global values averaged from the left anterior descending artery, left circumflex artery and right coronary artery. Coronary artery burden evaluation was performed in 98% of all available coronary segments. The inter- and intrarater variations were <10%.

2.6. Statistical analysis

Continuous variables were reported as mean ± standard deviation or median [interquartile range]. Comparison of baseline characteristics between tertiles of GlycA were performed by analysis of variance or Kruskal-Wallis as appropriate. Linear regression models were used to assess univariate and multivariable-adjusted associations between GlycA and LV mass/height\(^2.7\), NCB and LV mass/height\(^2.7\), and change in NCB and LV mass/height\(^2.7\) at 1 year follow-up. Unadjusted and adjusted mediation analyses was used to assess the contribution of NCB in the relationship between GlycA and LV mass/height\(^2.7\) as previously published.[17] Covariates included age, sex, hypertension, hypertension therapy, lipid therapy, biologic therapy for psoriasis, waist:hip ratio, psoriasis disease duration and severity. Two-sided P-values <0.05 were considered statistically significant. Stata version 15 (StataCorp, College Station, TX, USA) was used for all statistical analyses.

3. Results

3.1. Characteristics of the overall psoriasis study group and stratified by GlycA

Of 336 consecutive participants recruited, 123 did not have available LV mass, NCB characterization, or circulating GlycA measurements. The clinical characteristics of 213 participants included in the present study are summarized in Table 1. The mean age of the study cohort was 50.3 (±12.9) years; 59% were male with a median Framingham cardiovascular risk score (FRS) of 2.0 (0.5–5.4) and median Atherosclerotic Cardiovascular Disease (ASCVD) 10 year risk score of 3.2 (1.6–5.7) consistent with low cardiovascular risk. When the cohort was divided into tertiles of GlycA, there was an increase in psoriasis area sever-
3.3. A change in noncalcified coronary burden is associated with a favorable change in LV mass over one year

Finally, to understand if a change in NCB associated with LV mass over one year, 189 subjects who had repeat CCTA with available NCB and LV mass measurement at one year were included. At one-year, important markers of inflammation including GlycA (406.4 ± 5.8 to 386.6 ± 5.4, p = 0.005) and hs-CRP (3.7 ± 6.7 to 2.8 ± 4.1, p = 0.004) decreased. There was concordance in change in NCB and change in LV mass in both unadjusted models (β=0.18, p = 0.013) and in models adjusted for age, sex, hypertension, hypertension therapy, lipid therapy, biologic therapy, baseline NCB, and baseline LV mass (β=0.25, p = 0.002).

4. Discussion

In this study, we demonstrated that GlycA, a measure of chronic inflammation, was associated with LV mass, which remained significant after adjusting for cardiovascular risk factors. Early, subclinical CAD in the form of NCB also significantly associated with LV mass, and accounted for approximately 32% of the inflammation-LV mass relationship beyond important cardiovascular risk factors. Finally, there was an association between a change in NCB and a favorable change in LV mass over a one-year study period. Collectively, our findings support that inflammation-driven myocardial abnormalities occur incrementally beyond the effect of traditional cardiovascular risk factors, and that subclinical CAD may account for a substantial portion of this relationship.

It is well known that inflammation is critical for the development of CAD.[18] There is also increasing evidence that inflammation is integral in the pathogenesis of heart failure.[6] For example, inflammatory cytokines such as IL-6 and acute phase reactants such as hs-CRP are directly linked to both myocardial mechanical function[1] and myocardial structural changes and also are associated with increased incidence of heart failure and adverse clinical outcomes.[19] Furthermore, inflammatory markers including GlycA,[2] have served as important prognostic markers for disease progression and clinical outcomes in those with established heart failure.[20] However, despite intense interest in assessing targeted anti-inflammatory therapies for both prevention and treatment for heart failure, phase III clinical trials in treating inflammation in heart failure have mostly been disappointing.[6] A potential explanation for failure to translate biological observations to positive clinical trial outcomes may be explained by imprecise patient selection based solely on symptoms (NYHA class) to identify those patients who may be most likely to derive benefit from therapy. Indeed, in an exploratory analysis of the CANTOS trial in which elevated hs-CRP (>2 mg/L) was used as an inclusion criteria, treatment with canakinumab lead to a reduction in heart failure hospitalizations.[21] Such use of inflammatory biomarkers to optimize patient selection may be particularly relevant in heart failure with preserved ejection fraction (HFpEF), a heterogeneous condition where comorbidities such as obesity and hypertension induce systemic chronic proinflammatory states with associated metabolic derangements that eventually lead to myocardial structural and functional alterations.[10]

Identification of intermediate heart failure phenotypes is important for prevention of progression to clinical heart failure. Our results add to prior studies which attempt to identify the determinants of subclinical LV abnormalities. Large epidemiological studies have identified increased LV mass as a potent risk factor for increased cardiovascular and all-cause mortality.[22] Additional studies have related LV remodeling, defined as alterations in ventricular architecture, with myocardial functional impairment such as decreased regional systolic function and increased myocardial dyssynchrony by myocardial strain imaging.[23] Recent findings from our group showing the relationship between NCB and high-sensitivity troponin in a cohort of subjects with psoriasis but no known CVD support the notion that early vascular changes may drive myocardial injury.[24] The results from the current study showing the close relationship between subclinical CAD and LV mass in psoriasis...
further support the concept that chronic inflammation induces both coronary and myocardial abnormalities which may have additive risk for future outcomes. This may be especially relevant in the populations of obesity, hypertension, or diabetes mellitus where there is an increase in pro-inflammatory cytokines which may increase LV mass. Together, these data substantiate the need for additional studies focused on earlier, subclinical LV changes prior to development of clinical heart failure.

In this study, we showed a strong relationship between subclinical CAD assessed as NCB on CCTA and increased LV mass in the setting of chronic inflammation. This observation may be particularly relevant in HFrEF which is more associated with inflammatory markers, compared to heart failure with reduced ejection fraction (HFrEF), which often results from direct cardiac injury from ischemia or myocarditis.\[25\]

Chronic inflammation is known to trigger coronary microvascular endothelial inflammation and promote oxidative stress, leading to reduced nitric oxide availability, cyclic guanosine monophosphate content and protein kinase G activity in cardiomyocytes.\[10\] Subsequent myocardial hypertrophy and injury characterizes the development of clinical heart failure and promotes a vicious cycle of pro-inflammatory cell signaling.\[26\] Thus, identification of early, subclinical CAD may aid in identification of those at highest risk of development of heart failure in the future. In this context, our results of observing a change in NCB which was associated with a favorable change in LV mass further highlights the importance that early coronary artery disease may play in the risk of future heart failure in chronic inflammation.

**Table 2**
Characteristics of the cohort stratified by tertiles of GlycA.

| Clinical characteristics                               | GlycA 1st tertile (n = 73) | GlycA 2nd tertile (n = 73) | GlycA 3rd tertile (n = 73) | P value |
|--------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|---------|
| Age                                                    | 49.7 (12.6)                 | 49.1 (12.2)                 | 52.1 (12.8)                 | 0.36    |
| Male, n (%)                                            | 42 (58)                     | 46 (63)                     | 39 (62)                     | 0.50    |
| Hypertension, n (%)                                     | 15 (21)                     | 21 (29)                     | 23 (32)                     | 0.24    |
| Dyslipidemia, n (%)                                     | 31 (42)                     | 27 (63)                     | 26 (36)                     | 0.80    |
| Diabetes mellitus, n (%)                                | 7 (10)                      | 4 (5)                       | 6 (8)                       | 0.70    |
| Current smoker, n (%)                                   | 6 (8)                       | 10 (14)                     | 7 (10)                      | 0.55    |
| Framingham risk score                                  | 1.5 [0.4–4.4]               | 3.3 [0.5–7.3]               | 2.0 [1.0–5.5]               | 0.25    |
| ASCVD 10 year risk score                               | 2.3 [1.2–4.5]               | 4.6 [2.6–6.8]               | 3 [1.4–5.7]                 | 0.012   |
| Waist: hip ratio                                        | 0.94 (0.07)                 | 0.95 (0.08)                 | 0.96 (0.09)                 | 0.37    |
| Psoriasis area severity index score                     | 5.9 (6.0)                   | 6.6 (5.4)                   | 10.7 (9.5)                  | <0.001  |
| Medications                                            |                             |                             |                             |         |
| Cardiovascular                                         |                             |                             |                             |         |
| Anti-hypertensives                                      |                             |                             |                             |         |
| Lipid-lowering medications                             |                             |                             |                             |         |
| Diabetes medications                                    |                             |                             |                             |         |
| Psoriasis                                              |                             |                             |                             |         |
| Biologic therapy                                       |                             |                             |                             |         |
| Topical therapy                                        |                             |                             |                             |         |
| Light therapy                                          |                             |                             |                             |         |
| Blood markers                                          |                             |                             |                             |         |
| Total cholesterol, mg/dL                                | 186.9 (42.6)                | 189.3 (40.2)                | 181.0 (35.6)                | 0.46    |
| HDL-C cholesterol, mg/dL                                | 62.2 (23.2)                 | 56.1 (18.4)                 | 53.4 (15.0)                 | 0.02    |
| LDL-C cholesterol, mg/dL                                | 100.9 (33.7)                | 108.8 (32.5)                | 105.1 (31.0)                | 0.35    |
| Triglycerides, mg/dL                                    | 114.5 (75.7)                | 121.7 (61.7)                | 120.3 (63.8)                | 0.79    |
| Hs-CRP, mg/L                                           | 1.4 (0.3)                   | 2.5 (4.1)                   | 7.9 (9.9)                   | <0.001  |
| GlycA, μmol/L                                          | 338.3 (26.9)                | 398.8 (17.4)                | 484.6 (51.4)                | <0.001  |
| Coronary artery characterization on CCTA               |                             |                             |                             |         |
| Plaque present, n (%)                                   | 22 (30)                     | 22 (30)                     | 21 (29)                     | 0.91    |
| Total coronary burden (mm²×100)                         | 1.05 (0.32)                 | 1.28 (0.55)                 | 1.34 (0.53)                 | <0.001  |
| Noncalcified coronary burden (mm²×100)                 | 1.00 (0.32)                 | 1.22 (0.53)                 | 1.29 (0.53)                 | <0.001  |
| Dense calcified coronary burden (mm²×100)              | 0.05 (0.06)                 | 0.06 (0.10)                 | 0.04 (0.07)                 | 0.40    |
| LV characteristics on CCTA                             |                             |                             |                             |         |
| LV mass, g                                              | 104.9 (21.6)                | 113.0 (34.6)                | 116.8 (28.1)                | 0.015   |
| LV mass/height², g/m²²                                  | 24.6 (3.8)                  | 25.5 (3.8)                  | 27.7 (5.5)                  | <0.001  |

Values are mean (±SD), median [Q1, Q3], or number (%).

ASCVD indicates Atherosclerotic Cardiovascular Disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Hs-CRP, high sensitivity-C reactive protein; LV, left ventricular.

**Fig. 2.** Noncalcified coronary burden (NCB) partly mediates the relationship between GlycA and LV mass in unadjusted (A) and adjusted analysis (B).
In this study, LV mass was measured on CCTA using a fully automated AI segmentation algorithm. Although LV mass measurements have traditionally been performed using echocardiography and cardiac magnetic resonance (CMR) imaging, CCTA-derived LV mass measurements have been shown to be reliable and confer prognostic value. To account for body size differences, we normalized LV mass for height to an allometric power (height^2.7). Prior studies comparing different indices for normalizing LV mass found that LV mass/height^2.7, when compared to LV mass/BSA, identified a higher percent of LVH in patients who have hypertension and are overweight or obese.[15] Additionally, LV mass/height^2.7 when compared to LV mass/BSA, was associated with higher incidence of cardiovascular events linked to obesity-related LVH.[28] an especially relevant consideration in this study given the high prevalence of obesity in our cohort.

5. Study limitations

This was an observational study and thus subject to residual confounding even after adjustments in our statistical modeling. Furthermore, the observational nature precludes conclusions about causality and further studies designed for this purpose are needed to assess the role of early CAD in the pathway from inflammation to LV mass. Additionally, this was a relatively small sample size compared to other epidemiological studies investigating LV mass using CCTA or CMR. However, because the same CT scanner was used to obtain all CCTA scans and an automated AI algorithm was used for LV segmentation, our measurements of LV mass are highly objective and reproducible. The ability to obtain precise measurements will be especially useful in evaluating LV mass changes over a longer follow-up period, an important consideration given the long natural history of progression from LV dysfunction to clinical heart failure. Furthermore, we do not yet have enough clinical heart failure outcomes to correlate with LV mass characterization. However, the goal of this study was to understand the relationship between systemic inflammation with subclinical vascular and myocardial abnormalities. Future studies should also focus on earlier steps in the LV remodeling process prior to development of increased LV mass including understanding whether myocardial perfusion is deranged, refined tissue characterization using CMR, and translational studies to uncover cellular pathways which link systemic inflammation-driven cardiomyocyte dysfunction.

6. Conclusions

In conclusion, chronic inflammation was associated with LV mass in subjects with psoriasis after adjusting for important cardiovascular risk factors. Subclinical CAD in the form of NCB partly accounted for the relationship between inflammation and LV mass. Finally, there was a significant relationship between change in NCB and change in LV mass over one year suggesting subclinical atherosclerosis may play a role in increasing LV mass in chronic inflammation.

Contributorship statement

Design of work: WZ, NNM
Conduct of work and data acquisition: WZ, MT VB, PK, GAM, NP, JEA, JAR, AK, SMB, MYC, LYH, NNM
Data analysis and interpretation: WZ, MT, VB, GAM, AKD, AVS, NP, HLT, MPP, LYH, DAB, MC, NNM
Drafting the work: WZ, NNM
Review the work and providing input: all authors
Final approval: all authors
Guarantors overall content: WZ, NNM.

Declaration of Competing Interest

Dr. Mehta is a full-time US government employee and has served as a consultant for Amgen, Eli Lilly, and Leo Pharma receiving grants/oher payments; as a principal investigator and/or investigator for AbbVie, Celgene, Janssen Pharmaceuticals, Inc., and Novartis receiving grants and/or research funding; and as a principal investigator for the National Institutes of Health receiving grants and/or research funding.

All other authors declare no conflicts of interests in relation to the work presented in this manuscript.

Acknowledgements

We would like to acknowledge and thank NIH Clinical Center outpatient clinic-7 nurses for their invaluable contribution to the process of patient recruitment.

Funding

This study was supported by the National Heart, Lung and Blood Institute (NHLBI) Intramural Research Program (HL001693-05). This research was also made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation (DDCF Grant #2014194), the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, Elsevier, and other private donors.

References

[1] Rosen BD, Cushman M, Nasir K, Bluemke DA, Edvardson T, Fernandes V, Lai S, Tracy RP, Lima JA. Relationship between C-reactive protein levels and regional left ventricular function in asymptomatic individuals: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2007;49:594–600.
[2] Jiang S, Ogumoroti O, Ndumele Chiadi E, Zhao D, Rao Vishal N, Faishan Oluwaseun E, Tiluuskus M, Orvos James D, Benson E-M, Ouyang P, Michos Erin D. Association of the novel inflammatory marker Glyca and incident heart failure and its subtypes of preserved and reduced ejection fraction. Circulation 2020;1(3):e007067.
[3] Koppikar S, Colaco K, Harvey P, Akhtar S, Chandran V, Gladman DD, Cook R, Ede L. Incidence of and risk factors for heart failure in patients with psoriatic disease - a cohort study. Arthritis Care Res (Hoboken) 2021.
[4] Lerman JB, Joshi AA, Chaturvedi A, Aberra TM, Dey AK, Rodante JA, Salahuddin T, Chung JH, Rana A, Teague HL, Wu JJ, Playford MP, Lockbin BA, Chen MY, Sandfort V, Bluemke DA, Mehta NN. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation 2017;136:263–76.
[5] Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. Nat Eng Med 1990;523:236–41.
[6] Adamo LA, Rocha-Rengened C, SD Prabhu, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020;17:269–85.
[7] Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, Krishnamoorothy P, Ng Q, Aridi TZ, Salahuddin T, Natrajzan B, Lockbin BN, Ahlman MA, Chen MY, Rader DJ, Reilly MF, Remaley AT, Bluemke DA, Playford MP, Gelfand JM, Mehta NN. Glyca is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res 2016;119:1242–53.
[8] Akinkoluile AO, Burin JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc 2014;3:e001221.
[9] Gruppen EG, Kipphanen U, Connelly MA, Orvos JD, Bakker SJ, Dullaart RP, Glyca: a pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. PLoS ONE 2015;10:e019507.
[10] Paulus WJ, Tischge A. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–71.
[11] von Elm E, Ahlman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP, Initiative S. The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573–7.
[12] Orvos JD, Shalasurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. Glyca: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 2015;61:714–23.
[13] Bui V, Shannagb SM, Levine O, Jacobs M, Bandettini WP, Chang L-C, Chen MY, Hsu L-Y. Simultaneous multi-structure segmentation of the heart and peripheral tissues in contrast enhanced cardiac computed tomography angiography. IEEE Access 2020;8:16187–202.
[14] Bui V, Hsu LY, Shannagb SM, Tran L, Bandettini WP, LC Chang, Chen MY. Improving multi-atlas cardiac structure segmentation of computed tomography angiography: a performance evaluation based on a heterogeneous dataset. Comput Biol Med 2020;125:104019.
[15] Cuspidi C, Meani S, Negrì F, Giudici V, Valerio C, Sala C, Zanchetti A, Mancia G. Indexation of left ventricular mass to body surface area and height to allometric
power of 2.7: is the difference limited to obese hypertensives? J Hum Hypertens 2009;23:728–34.

[16] de Knegt MC, Haugen M, Jensen AK, Linde JJ, Kühlt JT, Hove JD, Kofod KF. Coronary plaque composition assessed by cardiac computed tomography using adaptive Hounsfield unit thresholds. Clin Imaging 2019;57:7–14.

[17] Teague HL, Aksentijevich M, Stanisky E, Silverman JD, Varghese NJ, Dey AK, El-nabawi Y, Goyal A, Dagur PK, Chen MY, McCoy JP, Playford MP, Hourigan C, Gelfand JM, Mehta NN. Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. J Invest Dermatol 2020;148:912–15 e1.

[18] Libby P, Ridker PM, Hansson GKL. Transatlantic Network on a. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129–38.

[19] Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB, Framingham Heart S. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486–91.

[20] Testa M, Yeh M, Lee P, Berman JW, Lejemetl TH, Fanelli R, Loperfido F. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 1996;28:964–71.

[21] Everett Brendan M, Cornel Jan H, Lainscak M, Anker Stefan D, Abbate A, Thuren T, Libby P, Glynn Robert J, Ridker Paul M. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation 2019;139:1289–99.

[22] Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of Echocardiographically determined left ventricular mass in the Framingham heart study. New England Journal of Medicine 1990;322:1561–6.

[23] Rosen BD, Fernandes VR, Nasir K, Helle-Valle T, Jerosch-Herold M, DA Bluemke, Lima JA. Age, increased left ventricular mass, and lower regional myocardial perfusion are related to greater extent of myocardial dyssynchrony in asymptomatic individuals: the multi-ethnic study of atherosclerosis. Circulation 2009;120:859–66.

[24] Zhou W, Abdelrahman KM, Dey AK, Reddy A, Uceda DE, Larteel SS, El-nabawi YA, Anzenberg P, Al Najafi M, Rodante JA, Keel A, Ortiz J, Teague HL, Erb-Alvarez J, Singh D, Joshi AA, Playford MP, Chen MY, Gelfand JM, Remaley AT, Bluemke DA, Mehta NN. Association among noncalciﬁed coronary burden, fractional ﬂow reserve, and myocardial injury in psoriasis. J Am Heart Assoc 2020;9:e017417.

[25] Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, Brunner-La Rocca HP investigators T-C. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 2015;17:1006–14.

[26] Castillo EC, Vaquiez-Garza E, Yee-Trejo D, Garcia-Rivas G, Torre-Amione G. What is the role of the inflammation in the pathogenesis of heart failure? Curr Cardiol Rep 2020;22:139.

[27] Klein R, Ametee ES, Yam Y, Dwivedi G, Chow BJ. Cardiac CT assessment of left ventricular mass in mid-diastasis and its prognostic value. Eur Heart J Cardiovasc Imaging 2017;18:95–102.

[28] de Simone G, Kizer JR, Chiniali M, Roman MJ, Bella JN, Best LG, Lee ET, Devereux RB. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 2005;18:191–6.